Table 1.
Patient baseline characteristics and response to treatment
| Characteristics, n (%) | N = 33 | Median [IQR] time (months) |
|---|---|---|
| Diagnosis according to the WHO classification [48] | ||
| GCB DLBCL | 13 (39.39) | |
| Non-GCB | 7 (21.21) | |
| High-grade BCL, NOS | 5 (15.15) | |
| T-cell rich large BCL | 3 (9.09) | |
| Primary mediastinal large BCL | 2 (6.06) | |
| Burkitt lymphoma | 2 (6.06) | |
| High-grade BCL, with MYC and BCL2 and/or BCL6 translocations | 1 (2.4) | |
| B symptoms | 22 (66.66) | |
| LDH > ULN* | 22 (66.66) | |
| ECOG performance status >1 | 5 (15.15) | |
| Bulky disease | 14 (42.42) | |
| Ann Arbor stage | ||
| I | 3 (9.09) | |
| II | 7 (21.21) | |
| III | 6 (18.18) | |
| IV | 17 (51.52) | |
| Extranodal involvement > one site | 10 (30.3) | |
| HIV+ | 2 (6.06) | |
| R-IPI risk | ||
| Very good | 14 (42.42) | |
| Good | 16 (48.48) | |
| Poor | 3 (9.09) | |
| Front-line treatment | ||
| Group 1 | ||
| R-CHOP or R-CHOP-like regimen | 23 (68.43) | |
| Group 2 | ||
| High doses of chemotherapy | 10 (29.04) | |
| Lines of treatment | ||
| 1 | 22 (66.66) | |
| 2 | 6 (18.18) | |
| >3 | 5 (15.15) | |
| Autologous stem cell transplant | 7 (21.21) | |
| CAR T-cell therapy | 2 (6.06) | |
| Response to treatment | ||
| Long-term complete response | 23 (69.69) | 72 [52–87] |
| Late relapse | 3 (11.54)** | 69 [53–70] |
| Partial response | 2 (6.06) | 40 [13–67] |
| Stable or refractory disease | 5 (15.15) | 13 [0–82] |
*
UNL = 480 IU/L.
**
This percentage is out of the total number of patients who presented complete response at the end of treatment (n = 26).
CAR-T, Chimeric Antigen Receptor; CBL, B-Cell Lymphoma; ECOG, Easter Cooperative Oncology Group; DLCBL, Diffuse Large B-Cell Lymphoma; GCB, Germinal Center B-Cell-Like; HIV, Human Immunodeficiency Virus; IQR, Interquartile Range; LDH, Lactate Dehydrogenase; NOS, Not Otherwise Specified; R-CHOP, Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone; R-IPI, Revised International Prognostic Index; ULN, Upper Limit of Normal; WHO, World Health Organization.